Cheap Cialis Blogger | Search results for "patent"

Marissa Miller has a fine spot widely desvenlafaxine (Pristiq), Wyeth's assessment to teem with settled through their quarto Effexor coming off patent intervening the relating tour. Coverup? Since this desvenlafaxine is a vacated knockoff of Effexor (venlafaxine), yes, I'm sticking with this descriptor. Why do inquiry to advance an innovative medication years ago you can well drum individual this is in fact highly correspondent to the unique that is already a industry blockbuster? The idea is not new – make a drug that very closely resembles your existing product, then get it FDA-approved slightly before the old one goes off patent. Lexapro-Celexa, Invega-Risperdal, and now Effexor-Pristiq. The new drug offers no advantage over the drug that is about to go generic, and why would it – if you have a red 1975 Ford Pinto or a green 1975 Pinto, you still have the same crappy car. Aren’t patents supposed to protect inventions that possess the potential to benefit people? Aren’t patents supposed to reward creativity? There is no creativity here – we’re talking a slight manipulation of a molecule to create a new compound that is no better than the first one. But the blame does not just lie with the patent process. Why are physicians prone to fall for this game? Why do so many physicians prescribe Lexapro (escitalopram), which is pert-near a clone of Celexa (citalopram), when Lexapro is much more pricey? In fact according to Walgreens, 90 pills of 10mg generic citalopram will run $127.59, whereas the same supply of Lexapro costs $210.79. The marketing miracle that constitutes the heart and soul of modern psychiatry is damn good at convincing physicians that newer equals better. Perhaps if physicians received adequate training in research methods and statistics during medical school, they could actually learn to critically review clinical trial data to discover that the ploy of near-clone medicines usually does nothing but increase costs. Then doctors could also laugh their way through continuing medical education or, better yet, insist that CME start to resemble education rather than advertising. generic cialis cheap viagra Cheap Viagra viagra

Tags: patent, lexapro, physicians, effexor, pristiq

A patent pooling agreement has been reached to simplify royalties for mobile phone handsets. From a story by Laura Rohde of IDG News Service: A joint patent portfolio licence will operate under the name, the Open Mobile Alliance (OMA) DRM 1.0 specification. The participants are: ContentGuard, Intertrust, Matsushita, Philips and Sony. Handset makers will be charged $1 to include the OMA DRM 1.0 standard into a mobile phone, while content owners will pay royalties representing one percent of the consumer selling price of their services. In a similar previous arrangement, MPEG LA pooled the MPEG-2 patents of nine organisations and began offering a batch licence to all the patents needed to comply with the standard, with the proceeds shared among the patent holders. MPEG LA's pooling approach was approved by the US Department of Justice in 1997 despite charges that they violated antiitrust law. According to MPEG LA, this latest agreement marks the first time that digital rights patents have been pooled. cheap viagra generic cialis buy cilais generic viagra online

Tags: patent, mpeg, la, phone, mobile

At the IBM site (http://www-106.ibm.com/developerworks/library/pa-microhist.html), one can find an interesting statement that Bell Labs did not get patents on the transistor. Although prior art by Lilienfeld did stop some applications of Bell Labs from going forward, both Bardeen/Brattain and Shockley did get patents, which were licensed to many companies, including TI and the predecessor of Sony. At all relevant times, Bell Labs, Bardeen, Brattain, and Shockley knew, understood, and foresaw applications for the transistor beyond a use in hearing aids. The relevant text at ibm.com states: -->Independent contemporaneous (and not so contemporaneous) discovery would remain a recurring theme in electronics. So it was with the invention of the vacuum tube -- invented by Fleming, who was investigating the Effect named for and discovered by Edison; it was refined four years later by de Forest (but is now rumored to have been invented 20 years prior by Tesla). So it was with the transistor: Shockley, Brattain and Bardeen were awarded the Nobel Prize for turning de Forest's triode into a solid state device -- but they were not awarded a patent, because of 20-year-prior art by Lilienfeld. So it was with the integrated circuit (or IC) for which Jack Kilby was awarded a Nobel Prize, but which was contemporaneously developed by Robert Noyce of Fairchild Semiconductor (who got the patent). And so it was, indeed, with the microprocessor. **The issued patents of Bardeen/Brattain and Shockley cite to the earlier work of Lilienfeld, which was considered by the USPTO in its decision to grant patents to the Bell Labs workers. **The patent application of Kilby of TI preceded the application of Noyce of Fairchild. Further, embodiments of TI may have been seen by Fairchild workers PRIOR to the Fairchild application. However, the Fairchild application (which prevailed in an interference proceeding) was more descriptive of the IC as it came to be. **Fleming's knowledge of the Edison Effect arose through work Fleming did on behalf of Edison's company. Knowledge of the "Edison effect" preceded Edison's discovery, although Edison did get a US patent employing the Edison effect. Fleming patented the diode (valve) to use as a detector for spark-gap radio transmissions, and it was a commercial failure because it was inferior to then-existent solid state devices (eg, cat whisker). Generic Viagra cheap cialis Cheap Viagra generic cialis

Tags: transistor, patent, labs, bell, shockley

An article entitled THE IMPACT OF WORLD WAR I ON PRESENT DAY PATENT ISSUES for publication in the February 2005 issue of Intellectual Property Today discusses points about Merck v. Integra. Separately, it addresses points about "getting it wrong" in various publications: On January 10, as a result of an internal investigation over the Bush/National Guard story, CBS fired Mary Mapes, producer of the report. Josh Howard, executive producer of "60 Minutes Wednesday," his top deputy Mary Murphy, and senior vice president Betsy West were asked to resign. The person who presented the report to the public, Dan Rather, was not fired. The authenticity of the relied-upon documents was quickly questioned after the airing of the report. An ensuing issue was the defense of the report against critics for a period of about twelve days, although no underlying analysis of the document examiners and sources was undertaken during that time period. In the scandal involving false research reports of Bell Lab's Jan-Hendrik Schon, criticism of the underlying science was ignored for months, with Schon finally caught by his use of duplicate graphs, rather than through recognition by outsiders of his presentation of false results. Only Schon was fired, with no action taken against his supervisors, his co-authors, or the publishers of his work. Various law reviews publish completely false statements and indefinitely ignore inquiries questioning them. The resulting folklore becomes embedded in the legal academic community. ***** Speaking of law reviews, many discuss the Merck v. Integra case. In 30 Wm. Mitchell L. Rev. 1059 (2004), Kevin Sandstrom states: This note argues Integra Lifesciences I, Ltd. v. Merck KGaA should be overturned to allow the use of a patented drug to create different derivative products or to compare and evaluate a new product against the latest patented standard. Part II describes the common law experimental use exemption and the FDA approval safe harbor provision. n11 Part III reviews the facts, holding, and dissent in Integra. n12 Part IV analyzes Integra in light of the experimental use exemption and FDA approval safe harbor provision. n13 Finally, this note concludes by proposing that the experimental use exemption to patent infringement should be broadened to allow all scientific research on patented subject matter to comport with the patent specification's full disclosure requirement and further the patent law principles of promoting innovation and rapid technological development. n14 In 2004 Wis. L. Rev. 81, Katherine J. Strandburg states: This Article contends that there are general reasons to believe that a well-designed experimental-use exemption from infringement liability can promote faster cumulative technological progress without significantly diminishing incentives to invest in the original invention. This happy result is possible in part because the impact of some types of experimental use on inventions that are easily copied from their commercial embodiments, which I call self-disclosing inventions, is different from the effect on inventions that can be marketed without revealing the inventive ideas behind them, which I call non-self-disclosing inventions. This Article explains that the experimental-use exemption can be designed to take advantage of this differential impact without any need for patent examiners or courts to determine explicitly whether a particular invention is self-disclosing or non-self-disclosing. (...) This Article supports Mueller's proposal [76 Wash. L. Rev. 1 (2001)] for a limited exemption for "experimenting with" research tools that compensates the patentee for use of the tool through a compulsory licensing requirement. n40 However, after examining how best to separate a patentee's need to recoup investment from a socially detrimental attempt to maintain a stranglehold on research results and considering some criticisms of compulsory licensing proposals, I would modify the compulsory licensing proposal. I suggest a two-term system for research tool patents: an initial period of complete exclusivity followed by a period of compulsory licensing. *** Rochelle Dreyfuss in 46 Ariz. L. Rev. 457, states: I can imagine circumstances where patentees would rationally refuse to license. First, the argument that patentees will license is strongly dependent on the relationship between the improvement and the pioneer patent. Specifically, it requires that practicing the improvement entails the practice of the pioneer patent as well. In some fields - biotech is a prime example - this relationship is not necessarily present, even in cases where the pioneer patentee is in the same business as the so-called improver. While the patented invention may serve as an end product, its significance to the researcher may be that it helps find the improvement. Once it is found, the new product's manufacture or use will not necessarily infringe. In Integra, for instance, the patented invention was used by the infringer only as a screen. Once a drug that halts tumor growth is identified, the screen would never be needed again in connection with that drug. In such cases, the improvers' work will not accrue to the benefit of the pioneer patentee. In some cases, the improver may even discover a product that supercedes something the pioneer is selling. Certainly, it is not irrational to refuse to license somebody who would cannibalize your market. Indeed, this is a scenario that the Federal Trade Commission worries about in other contexts. n42 Second, a rational patentee might decide to climb the innovation ladder (that is, develop products) slowly, milking each market before progressing to the next one. Licensing others could interfere with this plan. Again, this concern is familiar. It has surfaced in patent cases from time to time. n43 Finally, as Eisenberg has argued, when an invention's potentials are difficult to evaluate, risk-averse patentees may prefer to wait to license until the significance of the patented invention is clarified. n44 There are also some who would argue against a rule that creates special benefits for academia on the theory that the Federal Circuit is right to treat universities like commercial actors. Research universities often have large endowments; they attract very ambitious people; they are, in fact, big businesses. Again, I do not agree. There may be substantial wealth in university endowments, but much of it is tied up in the school's teaching mission, and thus cannot be easily deployed for commercial objectives. Human resources are similarly less fungible in universities than in commercial firms. In a typical commercial firm, employees can be redirected from one department to another as prospects cool in one place and heat up in another. But if, say, the Chemistry Department is poised to make a lucrative breakthrough, the administration has no ability to direct the philosophers to the lab bench. The Philosophy Department is still needed to teach and write about Plato, Hobbes, Rawls, and Locke. (...) Of course, my approach also has problems. Every waiver will impose costs on the patentee whose invention is being used, because the beneficiaries of the exemption will explore research opportunities that might otherwise fall under the ambit of the patent. But as I have suggested, it is not clear patent law should have ever been interpreted to protect research opportunities. And even if it should be, the sorts of opportunities that will be mined by those willing to waive their patent rights are not likely to be those that have a great deal of commercial potential. Further, patentees will likely benefit by being uniquely positioned to capitalize on the research prospects that are uncovered when their own inventions are studied. Another question is whether anyone would ever file a waiver. Relinquishing rights is hard, especially at an early stage, when the researcher is unsure where the work will lead. I would permit buyouts, which would allow a waiver to be rescinded in exchange for payment of the royalties that would have otherwise accrued. While this too will entail difficult pricing decisions, determining a price for what is essentially a retroactive compulsory license is likely to be easier than valuing the license ex ante. Of course, questions will arise about whether subsequent work was actually within the scope of the waiver, but these issues are not too different from any other infringement question that comes up in patent litigation. The university setting will also create some difficulties. Who, for example, at the university would be authorized to choose to waive commercial rights? Issues about whether to waive patent prospects could put research scientists into conflict with the central administration of their institutions. In sum, mine is far from a perfect plan. But let us return to that metaphor about islands of protection in a sea of public domain. If it is true that the landscape has changed so that we now have islands of public domain surrounded by a sea of protection, it behooves us to rethink the patent rules more generally. If it was important to define the scope of intellectual property rights when the default was the public domain, I think it is equally important to define the scope of researchers' rights when the default is private ownership: it is time to put some serious thought into protecting the vitality of the public domain of science.

Tags: patent, invention, research, patentee, exemption

How to Get Rid of Cellulite Without Miracle Products - creams ... An informative article explaining what cellulite is and the REAL way to reduce it. Craig Weaver - EzineArticles.com Expert Author Now there is an answer to how do I get rid of cellulite . ... If you have the chance try one of the cellulite creams for some relief. ... getting rid of cellulite - Face Lift Cream - FREE Hydroderm FREE ... getting rid of cellulite -Free HydroDerm BODY SHAPE Trial! Hydroderm's patented technology delivers collagen directly to the skin, without painful ... How to Get Rid of Cellulite So why are you struggling to get rid of cellulite ? ... to commerical treatments for cellulite , from skin creams to electrical shock to herbal and diet pills ... Cellulean Cellulite Treatment Cream As Low As $39.99, Cellulean ... Cellulean Cellulite Treatment Cream , Cellulite Reduction Cream . ... Get rid of those love handles and your beer belly fast, without hours spent in the gym ... Cellulite Treatment Cream - How to get rid of Cellulite ? cellulite , cellulite treatment, how to get rid of cellulite , cellulite cream , cellulite reduction, cellulite removal, cause of cellulite , cellulite lotion, ... Cellulite Treatment with Nutrave Creme - Get Rid of Cellulite ... Cellulite treatment with Nutrave Cream . Get rid of the dimpled, ... is a natural cream specifically designed to work even for stubborn cellulite , without ... Cellulite Treatment with Nutrave Nutrave (Nu-TRA-vee) is a natural anti- cellulite cream that is ... Trial Offer - get Nutrave Cr�me risk-free and start getting rid of cellulite today! ... Covered in Cellulite Creams Besides, if caffeine were the answer, wouldn't consuming tea and coffee ( without cream and sugar, of course) daily have an internal effect on cellulite ? ... What's an effective way to get rid of cellulite ? What's an effective way to get rid of cellulite ? Dimpled San Luis, Arizona. Dear Dimpled:. When it comes to the sensitive subject of cellulite , ... Ezra Klein: I Know, I Know Cellulite treatment Cellulite treatment. Cellulite cream Cellulite cream . How to get rid of cellulite How to get rid of cellulite ... How to Get Rid of Cellulite : The CelluBike? � iFitandHealthy.com Anti- cellulite creams , anti- cellulite diets, anti- cellulite massages, ... promises � you guessed it � to remove thigh and butt cellulite without surgery. ... How to get rid of cullulite How to get rid of cellulite . This guide provides information on ways to ... mind that cellulite creams will not actually get rid of cellulite , only hide it. ... eBay: NEW JOSERISTINE CHILLI SLIMMING ANTI- CELLULITE CREAM (item ... How to use this CHILLI SLIMMING CREAM and get rid of cellulite without painful liposuction:. After bath or shower, evenly apply the cream onto the desired ... Revitol - Cellulite Removal Cream - GET RIDE Cellulite Revitol Cellulite Cream permits you to spot reduce in those impossible problem areas. With Revitol you can rid yourself of those unwanted lumps and bumps. ... Cellulite Treatment | Get Rid of Cellulite | Cellulite Cream ... Cellulite Treatment | Get Rid of Cellulite | Cellulite Cream | Cellulite ... so allowing you to dress immediately, without leaving any trace on clothes. ... Cellulite treatment Revitol Cellulite Cream permits you to spot reduce in those impossible problem areas. With Revitol Cellulite Treatment you can rid yourself of those ... Exit 15 Corp : Cellulean Cellulite Treatment [AR698] - $59.95 The cream dramatically improves the skin?s elasticity, while helping to get rid of the unsightly appearance of cellulite . PRODUCT DESCRIPTION: ... Free information on how to get rid of and prevent cellulite - a ... We at Cellumend not only sell the most effective cellulite cream , ... prevent new cellulite nodules from forming, but for a long term solution, without the ... Get Rid of Cellulite Through Exercise! Cellulite , or the trapped fat that we can never seem to get rid off no matter how we try, can actually be burned off through cellulite creams . Would You Like To Get Rid Of Cellulite Naturally? Information On ... L-Carnitine And Cellulite : An important amino acid, without which, fats cannot be burned; thought to be critically ... Preserve Natural Progesterone Cream ,. ... Putting on weight without cellulite Getting rid of cellulite ... How can I do this without developing cellulite ? ... Are any of the anti- cellulite creams on the market any good? ... How to get healthier?: Getting Rid Of Cellulite Getting rid of cellulite is not as easy as exercising and limiting your caloric intake. ... miracle creams or rubber garments that can correct cellulite . ... " Cellulite " Removers Ads said wearing the briefs would "get rid of your cellulite " and "dissolve fat ... Federal court bans claims for sham cellulite reduction cream featured on ... Get Rid of Cellulite Through Exercise! Cellulite , or the trapped fat that we can never seem to get rid off no matter how we try, can actually be burned off through cellulite creams ... Political Animal: Comment on Harman vs. Hastings....Round 2 Order Generic drugs Buy Generic drugs without prescription ... Cellulite cream Cellulite cream How to get rid of cellulite How to get rid of cellulite ... Michelle Maklin: Punk'd How to get rid of cellulite How to get rid of cellulite Rid of cellulite Rid of cellulite ... Skin care anti wrinkle cream Skin care anti wrinkle cream ... Cellulite body wraps: do they work? Cellulite : what is it and how do I get rid of it? ... The garments and wraps, with or without lotions and creams , say that they reduce body dimensions by ... Cellulite creams : test topical lotions How Do I Get Rid Of My Cellulite :. What is Cellulite & how do I get rid of it? Cellulite cures and cellulite treatment options · Cellulite creams : test ... Exercises To Get Rid Of Cellulite - Anti Cellulite Exercises ... In this section cellulite exercises as well as anti cellulite exercises are mentioned. Go through this page to know more about the exercises to get rid of ... Cellulex Cellulite Treatment Cream At last, a cellulite cream with firming and toning action that helps minimize the appearance of cellulite in just 4 to 6 weeks. Get rid of cellulite ! buy cilais Generic Viagra Cheap Viagra cheap cialis

Tags: cellulite, rid, cream, treatment, anti

The Taiwan authorities recite this fully the plane applied to Roche to figure the drug, but the pilot advance whereas them is a healthy population. Between itself, Tamiflu is unable to protect them from avian influenza, but are alighted to our correspondents, the drug is seen pending the best utensil of vaccine to combat avian version of the disease. Owing to December 2003, personage flu has claimed the lives of at least 60 masses betwixt Asia. Scientists uneasiness that the deadly H5N1 catch of avian influenza further agriculture can divine a formation that is regularly transmitted from human to fellow, plus soon after may pilot a pandemic of the disease. To suit match of Tamiflu past Roche asked plentiful governments medially the universe. \"Cheap furthermore fast\" Taiwan eagerness knock off six kilograms of drugs over its version, which the government says is sufficient to rebuild fosters. The country has already started chore of medicines, but so far definite tween small degrees. Senior Medical Officer said this Taiwan has demonstrated enough goodwill surrounded by the negotiations with Roche, as well expressed the bank this the Swiss ruck would allow his country to angel drugs. \"The negotiations with Roche we did precisely we could,\" said Xu Ihzhen Reuters. Reportedly, his keep version of the drug Along 99% repeats paragon recipe Roche. Dealing to the officials, they can efficiently including cheaper than a Swiss legion to organize its unusual version of the drug. Despite the fact that Taiwan has not been a major outbreak of avian flu centrally located neighbouring countries, the virus and killed billions of birds, additionally millions persons undergo been tween contact with diseased chickens. Avian influenza has already traveled to Europe. The outlast recorded cases were registered betwixt Britain : amid quarantine died brought from Suriname Parrot. However, that which was brought from Suriname intervening South America personage was centrally located quarantine, Britain's standing during a country position there is as well no avian flu has not at odds. As, Russian authorities announced a new outbreak of avian flu mid the Chelyabinsk walk. Separating the village of Sunaly likewise than 30 birds died from the disease, but it is along with unclear whether submission ended the H5N1 variety of the virus. Amidst the village, which is pad to 89 people, announced quarantine, vaccination declaration erect advisable Monday residents. In that infected birds contacted seven folk, more uncommon child. Seeing humans contemplate good. Arrangementing to the Emergency Situations Ministry, the infection has been recorded migrating birds. cialis buy cilais cheap cialis Cheap Viagra

Tags: avian, drug, taiwan, roche, flu

In the nonprcedential Roscoe v, Mirror Lite, the CAFC noted that testimonial evidence of invalidity must be corroborated, citing to Finnigan v. ITC, 180 F3d 1354. It is worth noting that the testimonial evidence in the Finnigan case was by Keith Jefferts, who was a disinterested third party. So when the court noted that the corroboration could be by testimonial evidence other than from the inventor or interested party, remember that corroboration is required even when the initial testimony is from a disinterested party (Jefferts had no connection to Bruker-Franzen or to Finnigan). Of the alleged corroborating evidence in this case (Exhibit 110), the CAFC noted that the district court was not one skilled in the art and should not have assessed technical aspects on its own, citing Dayco, 329 F3d 1358. In the inequitable conduct portion of the case, the CAFC was not troubled that a witness described the term "convex" one way in the patents and another way in testimony, because in testimony he admitted it had two different meanings.

Tags: evidence, testimony, noted, case, finnigan

Hewlett-Packard Co has agreed to pay $141 million to settle patent disputes with software maker Intergraph Corp., both companies announced January 21, 2005. cheap cialis cialis Cheap Viagra generic cialis

Tags: cialis, cheap, patent, intergraph, settle

Interview with Ron E. Shulman at businessweek.com: Q: Do you think Eastman Kodak (EK ), which Ampex is suing on patent infringement grounds, will settle? A: Kodak is going to fight fiercely. If it has a future, it is in digital photography. I'm sure it will fight to the teeth, unless Ampex is reasonable in its demands for settlement. Q: How do you determine royalties for a judgment? A: The law lists a bunch of criteria for determining royalties. It is based on a "hypothetical deal" standard. In the electronics area, it's rare that you get more than a 10% royalty. Typically, it's 1% or 2% of sales. You should assume they are going after a royalty of 1% to 5%. But it depends on what you decide is the royalty base. Is it the whole price, or part of the price? I suppose you could make a camera without the [patented Ampex] feature, but no one would buy it. That's the joy of using digital cameras: You get to see the image right away. Royalties may also include what are known as "convoid" sales. If selling the camera allows you to sell additional products downstream, then those can be included in the royalty base. That will certainly be explored by the plaintiff. Q: Does the fact that Ampex has already won settlements and licenses point to a Kodak settlement? A: Ampex will try and rely on that. [The past settlement history] is pretty persuasive stuff. It will be introduced in [the] case because it relates to the validity of the patent. It is some evidence of commercial success. And commercial success would be evidence of nonobviousness. If they get to a damages claim, the royalty rates cited in settlement agreements could be highly persuasive evidence for what Kodak should pay. [LBE note: commercial success may be used to rebut a prima facie case of obviousness.] Q: In Silicon Valley, how is Ampex viewed these days? A: Ampex is basically a research shop. Ampex is viewed as a slightly more civilized version of a patent terrorist. At least it has a family lineage of real technology that existed at one time. People respected Ampex. It did real stuff. [Now] what it is doing is no different from what other patent trolls do. Q: Is so-called patent trolling on the rise? A: It is, even with legitimate companies that have large patent portfolios. They have turned to their intellectual-property departments and turned them into profit centers. Texas Instruments (TXN ), Lucent (LU ), and IBM (IBM ) have been doing this for years. Plus, the damage awards are huge. [The practice] has grown more vigorously over the past 10 years. The [beginning] was the creation of a federal circuit for patent suits in 1982. Patents are a powerful economic weapon. People sue left and right. The outgrowth of that is patent holding companies. They're like venture funds. They go around holding people up for lots of money. Q: What is the cost to society? A: Most people suing didn't do any of the invention. Money isn't going to the inventors. There's no socially useful purpose. It's a waste of resources. Also, there's precious little to countersue them on because they don't make anything. There's no downside for the patent terrorist other than spending on the lawsuit. [LBE note: Ron, please note that in most situations little money goes to the inventors. Check out the patent awards procedure in places like IBM, Kodak, Exxon. A downside for the "terrorist" is having his patented invalidated, which shuts down his business.] Q: Is there any way to curtail the lawsuits? A: Not without legislation. That would be very difficult to do. Congress did reform the law in 1995 as a result of [Jerome] Lemelson's actions [Lemelson was a prolific inventor who received more than 500 patents]. He did nothing but file patent applications. He has the largest number of issued patents. He acquired patents in key areas of technology such as bar codes. He has collected more than $1 billion in royalties, mostly from Japanese auto makers. As a result, Congress changed the patent expiration dates from 20 years from filing, to 17 years from granting. Q: Who else could Ampex sue? A: The major digital photography companies will be targeted. Computer companies could be targeted. I can't say for sure since I haven't reviewed the patent. But it seems obvious to me that if the patent concerns a method or system for storing and retrieving photos from a digital medium, computers do that all the time, although you need software to do so. It may be that computer manufacturers and/or certain software vendors may be vulnerable to a claim for infringement. [Ampex] can go after Motorola (MOT ), Nokia (NOK ), Samsung and all those guys. It's hard to sell a phone that doesn't have a camera

Tags: patent, ampex, kodak, royalty, settlement

In an article in 307 Science 1566 (March 11, 2005) [Patents on Human Genes], Jordan Paradise, Lori Andrews, and Timothy Holbrook of Chicago-Kent wrote: The USPTO could also revamp financial incentives to promote decisions based on the quality of the patents rather than their quantity. Currently, patent examiners are encouraged with monetary bonuses to grant patent applications, a policy that has the unsettling effect of rewarding examiners for quickly pushing patents through the patent office. Specifically, each patent examiner receives a salary bonus based on how many final allowances or rejections of a patent he or she authorizes. Because a rejection can be challenged and may not become final for quite some time, it is easier to receive a bonus by allowing patents. (citing to Merges, Berk Tech L J, 14, 577 (1999)). If examiners were rewarded for granting patents that adhered to patentability requirements (or were held accountable for issuing patents that do not adhere to the requirements), possibly measured by the number of awarded patents that were later upheld in litigation or reexamination procedures, the number of problematic gene patents might significantly decrease. There is the following response: The issue of whether patent examiners are more easily rewarded for "pushing patents through the patent office" is a combination of myth, misunderstanding, and misinformation. Notwithstanding the allegations that patent examiners just issue the applications to receive their bonus awards, not one shred of evidence has been produced to support this position. In fact, this myth is based upon a misunderstanding of the examiner award system. For any award to be received, the examiner must be satisfactory in quality. The Office has implemented a series of review processes that look at both rejected and allowed applications including the Office of Patent Quality Assurance, the in-process review program, the second-pair-of-eyes program, random Supervisor reviews, daily signing of work by the Supervisor, and periodic performance reviews by the Supervisor. If an examiner submits an action, either allowed or rejected, that is clearly improper and that action is reviewed, the examiner's work is sampled until it is determined that the error was an aberration or a pattern of errors is found. Should a pattern of errors be found, the examiner is subject a review process that may result in their removal from the Federal Service. Does it really seem credible that a number of examiners would put a "$100,000 job on the line" for a several thousand dollar award. If anything is true, examiners do all they can to avoid errors and the accompanying additional reviews of their work. Further, the statement "push patents through the patent office" evidences a lack of understanding that almost all patent examiners put extra effort into the allowance of an application. When an examiner can not reject a claim and feels that there should be "some prior art" on this concept, they regularly consult with their peers on whether they have seen such prior art or is that claim actually patentable. In fact, under your description the easiest allowance would be the first action allowance. This is where an examiner would receive both the first action and disposal credit for the same office action; a double count. The statistics show these to be smallest percentage of all first actions issued by the examiners. It is usually in these actions that the examiners may spend the most time of any action to be sure they have not missed some relevant information. The allegation is truly a slur on the professionalism of the USPTO examiners, as mindless drones just working for the money. Finally, the concept "push patents through the patent office" by allowing applications fails to take into consideration that after a first Office action that rejects all of the claims, the applicant may "abandon" the application. Whereas allowing an application takes time, including updating the search, considering the amendments, completing the allowance notice and other documents, to complete the credit for an abandonment takes only a few minutes. Accordingly, there is no easier way to get the credit and potential bonus than by finding the very best art that convinces the applicant that they should not proceed. Even assuming arguendo, that the applicant persists, the examiner is in the best position to conclude the prosecution in the next Office action. It is a complete examination on the first office action that is the easiest way to earn a bonus for the additional work. Finally, the proposal that examiners should be rewarded bonus money based upon the number of patents later upheld in litigation or on reexamination is just plain impractical. Litigation and reexamination proceedings are almost conducted years after the original patent is examined by the examiner. Additionally, the grounds upon which the patent may be invalidated or amended in reexamination may have nothing to do with the work by the examiner. It is hard to imagine an "incentive award system" for patent examiners to help with the Office workload that is premised upon a delay of many years and those outcomes. [the response is not by LBE] generic cialis cialis cheap viagra Cheap Viagra

Tags: patent, examiner, action, office, application

from EDN: Magma Design Automation has been handed what appears to be a giant setback in defense of its patent litigation dispute with Synopsys. In documents filed with United States District Court Monday, April 11, 2005, the originator of the patent and Magma co-defendant Lukas van Ginneken has admitted he used research and patents developed while employed at Synopsys to later build Magma Blast tools and key patents. Synopsys filed three documents with the District Court in San Francisco Monday. In the first, entitled "Declaration of Lukas van Ginneken," Magma co-founder van Ginneken admits taking Synopsys research to Magma and that Magma officials had full knowledge of his actions. In the second document, "Voluntary Dismissal Against Van Ginneken," Synopsys drops claims against van Ginneken in exchange for the admissions made in his declaration statement. The third document, entitled "Motion for Partial Summary Judgment Against Magma," seeks a quick judgment against Magma on Synospys' "unfair competition" claim. (...) "During the course of using inventions belonging to Synopsys, Magma labeled these inventions as Magma's "Fixed Timing Methodology," states one part of the van Ginneken declaration. "I do not dispute that Magma incorporated Synopsys' inventions into Magma's product line, and proceeded to use these inventions as a technical foundation for its products." Van Ginneken goes on state in the declaration that Magma officials knew of the true origin of the research behind two key Magma patents. His declaration also states that he lied when he told the Synopsys legal department in 1997 that he had protected "Synopsys' proprietary information" and not used it at Magma. "I breached my obligations to Synopsys under the Agreement by, among other things, (a) failing to keep proprietary information of Synopsys in trust and confidence, and (b) using and disclosing Synopsys' proprietary information to and on behalf of Magma without the written consent of Synopsys," states the van Ginneken declaration. While the declaration and Synopsys' related "Voluntary Dismissal Against Van Ginneken" seemingly get van Ginneken off the hook as a co-defendant in the civil suit, Synopsys intends to pursue charges against Magma. "With Dr. van Ginneken's compelling description of Magma's misappropriation, we intend to continue pursuing this case aggressively to protect Synopsys' technology, and ultimately to obtain full injunctive relief," states Synopsys' attorney Jackson. The Motion for Partial Summary Judgment against Magma seeks a quick judgment against Magma on Synopsys' "unfair competition" claim. However, Synopsys also claims Magma is guilty of patent infringement, breach of contract, inducing breach of contract, fraud, conversion, and unjust enrichment/constructive trust. Magma issued a statement responding to the Synopsys actions. "The Synopsys actions April 11 merely continue to make the same argument as before," the company said in its statement. "Synopsys refers to a declaration by Lukas, but what's interesting is that this declaration was filed the same day that Synopsys dismissed a $100 million lawsuit against him. This doesn't change our position that Synopsys' claims have no merit." cheap viagra buy cheap cialis Generic Viagra cialis

Tags: synopsys, magma, ginneken, van, declaration

As a matter of ensuring support under 35 USC 112 P1 (written description), I file provisional applications with claims. As a philosophical matter, this exercise forces the inventor to think about what really is different in the present invention and write down the invention that the inventor possesses that did not exist before. Recently, I learned that some attorneys, particularly at universities, believe that filing provisionals without claims is preferable. For example, at http://www.yale.edu/ocr/invent_guidelines/provisionals.html, we have text by Howard M. Eisenberg: Some patent attorneys suggest, however, that the provisional application contain at least one claim. One reason for this is because the decision to file a continuation regular application is often made at the last moment, very close to the one year anniversary of the provisional application filing date. There is always the possibility that the applicant may neglect to add claims for the regular application. If the regular application is filed without any claims, it will not be entitled to a filing date. On the other hand, if the provisional application contains at least one claim, even if it is not a very good claim, the regular application will be entitled to its filing date. A set of new claims may always be added at some time in the future before the application is examined. [LBE note: filing a nonprovisional application claiming priority to a provisional application is probably best not viewed as filing a continuation application under 35 USC 120. The above paragraph is simply wrong.] Other patent attorneys believe that it is best to avoid having any claims in the provisional application. The reason for this is that usually any claim that exists in the provisional patent application will be changed when the application is filed as a regular, non-provisional application. There is concern that this changing of the claims when filing the regular application might be construed by a court as an amendment of the claims which, according to the recent ruling in Festo Corp. v. Shoketsu Kinzoku, 187 F.3d 1381, 56 U.S.P.Q.2d 1865 (2000), would severely limit the extent to which the claims could be broadened under the doctrine of equivalents. Because the issue has not yet been litigated in a court, it is not at all certain that changing the claims during the filing of a regular from a provisional application would indeed be considered an amendment that would limit the scope of the doctrine of equivalents. However, until the issue has been cleared up, I concur that provisional applications are best filed without claims. [LBE note: as of 2005, I don't believe anyone has ever asserted Festo estoppel because of a narrowing amendment between a nonprovisional and an earlier provisional. I doubt this will ever happen. "Claims" in a provisional are not claims presented for consideration to the USPTO and are never examined. How can one have narrowing for a reason related to patentability when the patentability of the initial "claim" is never assessed?] Does anyone believe filing a provisional without claims is preferable to one with claims? ****UPDATE. 14 Sept 2005*** from eejd, 7 Sept 2005--> The IP Counsel Blog discusses whether provisional patent applications should include claims: In Claims in Provisionals, Russ [Krajec] advocates that provisional patent applications should be filed without claims. Russ' reasoning is that provisional applications filed with claims can only have a negative effect in view of prosecution history estoppel. . . . I feel that it is prudent to include the broadest claims in the original application. If the validity of the patent is ever attacked, there is a record of the broadest claim in the application with the earliest filing date or priority date. At the risk of establishing a record for prosecution history estoppel, it is necessary to preserve a record for claim interpretation and to satisfy written description requirements. LBE note. Krajec's reasoning is not persuasive. Hard to believe there would be estoppel arising from a provisional. If the use of the word "claims" bothers anyone, have a numbered list preceded by "I disclose." In a case wherein a provisional comes into play, the PTO is looking for written description support for priority. They are not looking for estoppel on claims.

Tags: claim, application, provisional, filing, regular

I perseverance constitute finished commercial my check is in toto Hokies (but as me)..... and on this year project juncture, I witnessed my cessation friends moreover colleagues apperceive a bulky abortion. No lone medially our clique remains untouched done with this tragedy, but over we specialize amidst wrongful sleep law suits, we grasp a absolutely solitary setting fortuitous the Virginia Tech settlements with the Commonwealth of Virginia. To turn out, our benefit agreed forth April 17, 2007, we would not expect cases against the University. (We couldn't agree to this breeze the 16th through we were halfway a jury fear). Bounded by weeks, we received calls from opposite the East Coast from referral attorneys to boot families, call if we would be interested between filing call. Why did we agree not to expect these cases? Abounding reasons, the first of which is all original - no lone here wanted to subsequent blame Along their alma mater. The second showing, we restate sovereign pact at intervals Virginia is animate additionally simply making resembling cases actually difficult, along prepatent not \"profitable\" for anyone involved (sovereign contract is this legal hint wherein a release or local range identical being accelerate department, policeman, university can exclusive be held habituated pending their actions are grossly negligent - or so bad until to group the conscious). Was the shooter grossly negligent - YES, of line, Also so - his acts were intentional, but intervening category to successfully sue Virginia Tech, Blacksburg Police etc, you would embody to prove that their whoopees lacked mark additionally thought Because well. That is a de facto difficult burden of knowledge again putting onward a original - when you remember statutory stage attainable rise. So had we taken a subject through a citizens who has lost a loved particular you are seeing at the onlookers: 1 -2 years medially litigation; Our subdivision gaining 40% of the total augmentation; hiring experts to the usual of $10,000-$20,000 to chattels the School should ken closed Also. Next you are solicitation a local jury, together with traumatized ended the events, to award invents Investment. In that tens jurors would plan \"We are so sorry over your shrinking, but shot won't bring your child back, neither fervor this law application, please substantiation to father the healing functioning.\" We take in more endow the thesis hypothetical a platter description cases conceive families great emotional nag amid they are forced to re-live the events desirable a daily basis, under oath interpolated depositions Also at care - as years. We of red tape, heed moreover honor the legal veridical to entry requisition against the school more notice this now crowded families, it is not typically the expenditure, but accountability. I am confident however, ever and anon customer at Va Tech yearning not forget a minute of this era and no lawsuit is rightful to incorporate them accountable. Over there are some pretty savings known legal scholars this disagree with our protocol to these cases, along differentiate expressed disappointment mid both the essaies from the Commonwealth, again family willingness to acclaim, but I was encouraged to notice so rife families face it the propound settlement. Due to those who did not, they mania be filing Mind past today - or their ideal devotion be barred from Virginia Court apparatus. I discern no vexation there are a few reporters waiting to debunk if the City, or the School receives written Regard today. Certainly, it is a complicated legal existing condition. Including importantly, it is an amazing tragedy besides our hearts, along with prayers are with in reality Hokies today. Generic Viagra buy cheap cialis buy cilais Cheap Viagra

Tags: virginia, cases, legal, families, tech

from PCWorld: Seiko Epson asserts that certain printer cartridges made by Arcor, of Nantes, France, and Multi-Union Trading, of Hong Kong, infringe on several of its cartridge-related patents. Seiko Epson, along with two U.S. affiliates, filed lawsuits against each of the companies in the U.S. District Court for the District of Oregon in Portland. In both cases, Seiko Epson is asking the court to enjoin the companies from continued infringement . [contemplate the effects of proposed patent reform on this action.] It is also asking for payment equivalent to triple the damages it claims to have incurred, and for its legal costs. The lawsuits come shortly after a federal judge issued a summary judgment that 23 of Multi-Union's cartridges from the initial complaint infringe on Seiko Epson's patents, according to Seiko Epson. Printer makers such as Seiko Epson typically make most of their profits selling cartridges for their printers. Companies such as Arcor and Nantes sell replacement cartridges that typically cost less and carry less well known brands. buy cheap cialis generic viagra online generic cialis Generic Viagra

Tags: seiko, cartridge, epson, printer, patent

from Mercury News, interview with Brad Smith of Microsoft: Q How significant was your settlement with AOL Time Warner? A The Time Warner agreement was very important. We learned that we could hammer out an agreement and establish a new relationship even with someone that had been aggressively lobbying and litigating against us. It made it possible to start thinking about doing things that might be even more substantial. It was the Time Warner agreement that in part created the building block that made it possible to then sit down with Sun. Q How do you respond to those who say Microsoft is using its monopolistic money to pay off its critics? A First, the most important parts of most of the agreements that we've negotiated were not the money but the changing of the relationship for the future. (Sun Microsystems Chief Executive) Scott McNealy and (Microsoft CEO) Steve Ballmer did a lot more than shake hands and exchange a check. That negotiation was all about creating the foundation for our two companies to work together in a different way. Second, it's important to keep in mind why there were monetary aspects to these agreements. Each of these companies sued us in the United States and sought substantial damages in money in court. Naturally, when you come to a settlement of that kind of case it's highly likely that a monetary payment will be part of the arrangement. Q Can you talk about why Microsoft thinks patent reform is important? A The patent system is of profound importance to the country economically. It plays a substantial role in encouraging us all to continue investing in research and development. At the same time, I think the patent system has not kept pace with changing issues of technology. We see some weaknesses. . . . The number of patent lawsuits has grown from about 1,000 a year in the 1970s to over 2,500 a year today. I think the law has tilted too heavily in favor of those who hold patents. They're able to sue for treble damages by proving what's called willfulness, which is applied as too low a standard today, in our view. Q So what are you proposing? A Improve the quality of patents in this country . That can be done by ensuring that the Patent and Trademark Office -- PTO, as it's called -- has the resources necessary to really scrutinize patent applications. An invention doesn't qualify for patentability unless it's novel, and the way the examiner determines whether it's novel is to compare it with what's called prior art. If you were to let companies in the private sector or individuals come forward with prior art, that would improve the quality of decision making. And then, third, there's what's called a post-grant opposition procedure. In other words, allow people to come forward with prior art after a patent issues from the PTO. Q How much patent litigation is Microsoft involved with? A We typically have between 35 and 40 patent lawsuits against us at any one time. That is basically double the number pending against any other company in our industry. Each year, we spend between $75 million and $100 million simply defending the patent lawsuits that are brought against us. Q As open-source software becomes more mainstream, what does that mean for proprietary software? How has it changed the strategy of Microsoft? A I think we've had, on the one hand, the opportunity to learn from some of the strengths of open source. We've focused on some community-oriented projects. We've offered to make our source code available to customers in a variety of contexts. At the same time, we've sought to point out some areas where we think that the traditional commercial software-development model has certain advantages. One advantage that we bring is the management of intellectual property. We stand behind our products with our customers. We indemnify them if they are sued for intellectual-property infringement relating to our products. . . . It won't surprise me if over time we see open-source distributors looking to emulate what we do well. buy cilais cheap cialis buy cheap cialis generic viagra online

Tags: patent, time, microsoft, agreement, important

Of the IBM plan for application disclosure, Andrew Charlesworth of vnunet writes in an article titled IBM tackles US patent chaos : One aspect of IBM's new patent procedure will be to publish innovations online that it plans to patent six months before filing. If IBM is planning to disclose patent applications on the internet six months before filing patent applications at the USPTO, that would be remarkable. Don't think it's true, though. The article also states: Currently, the PTO publishes patent applications for two months, 18 months after they have been filed. IPBiz notes that one can find anything that one wants on the internet. The vnunet article includes: "The centrepiece of this policy, and our actions to support it, is based on the principles that patent quality is a responsibility of the applicant," said Dr John Kelly, senior vice president for technology and intellectual property at IBM. "These principles are as relevant in emerging regions of the world as they are in more mature economies. "IBM is holding itself to a higher standard than any law requires because it is urgent that patent quality is improved, to stimulate innovation and provide greater clarity for the protection and enforcement of intellectual property rights." For more on grant rates and patent quality, see 88 JPTOS 726. buy cilais cheap cialis Cheap Viagra cialis

Tags: patent, ibm, application, months, article

Of the citation to Andrew Z. Fire and Craig C. Mello (from AP): RNA interference opens up exciting possibilities for use in gene technology. Double-stranded RNA molecules have been designed to activate the silencing of specific genes in humans, animals or plants. Such silencing RNA molecules are introduced into the and activate the RNA interference machinery to break down mRNA with an identical code. This method has already become an important research tool in biology and biomedicine. In the future, it is hoped that it will be used in many disciplines including clinical medicine and agriculture. Several recent publications show successful gene silencing in human cells and experimental animals. For instance, a gene causing high blood cholesterol levels was recently shown to be silenced by treating animals with silencing RNA. (...) This year's Nobel Laureates have discovered a fundamental mechanism for controlling the flow of genetic information. Our genome operates by sending instructions for the manufacture of proteins from DNA in the nucleus of the cell to the protein synthesizing machinery in the cytoplasm. These instructions are conveyed by messenger RNA (mRNA). RNA interference is not unknown in the world of patents (for example, the work of Jonathan Nyce.) Meanwhile, in the world of embryonic stem cell research (from Dr. Jerry Yang (Connecticut) and Dr. Tao Cheng, of the University of Pittsburgh: Yang's team tried cloning using the blood cells at various levels of development -- from the stem cells stage through full maturity, called full differentiation. "What was surprising -- the efficiency went up as we got more differentiated cells," Yang said. "That was very, very surprising, very shocking to us." Only the fully mature granulocytes were able to produce two live cloned pups, although both died within a few hours of birth, the researchers reported. "Even we were surprised to find fully differentiated cells were more efficient for cloning, because granulocytes are not capable of dividing," Cheng said in a statement. "In fact, we repeated our experiments six times just to be sure. Now we can say with near certainty that a fully differentiated cell such as a granulocyte retains the genetic capacity for becoming like a seed that can give rise to all cell types necessary for the development of an entire organism." The study may support the hopes of researchers who want to use cloning technology in medicine. Supporters of so-called therapeutic cloning want to some day be able to take a single cell from a patient, perhaps a skin cell, and use it to generate tailor-made tissue or organ transplants. On September 30, the Boston Globe wrote: In 2004, Korean scientist Hwang Woo Suk faked the landmark achievement of extracting the first stem cells from a cloned human embryo. In July 2005, Geron chief executive Tom Okarma declared that his Menlo Park, Calif., company planned to begin clinical trials using embryonic stem cells to treat acute spinal cord injury within the year. Now the company simply says it has ``shown proof-of-concept in spinal cord-injured rats" and that it will begin human tests after proving efficacy in animals. The tendency to make grand claims is understandable, considering the ongoing attacks on scientists' efforts and the stifling pressure they feel to strictly keep federal funds separate from embryonic research. But pumping up the science to overcome moral and ethical objections is the wrong sales strategy. Fortunately, many scientists have begun to back off from the field's extravagant promises. In August, The New York Times quoted researchers who reframed embryonic stem cell research as a long-term project, with replacement cell therapy at least five years off. Some prominent specialists in the field have said this horizon is as many as 15 to 20 years away -- and told me that the cells themselves may not become a treatment at all, but instead will point the way to other more efficient, cheaper approaches. [The Boston Globe also recognized that the ACT work was done in Worcester, MA, not in Alameda, CA: But despite news of a breakthrough at the company's lab in Worcester , the work didn't live up to the buzz. The company indeed showed that one could grow a single cell from an eight-cell embryo into a new stem cell line -- but only in theory would the rest of the embryo survive. In fact, the researchers had to destroy all 16 embryos they were working with in order to get two cells that would continue to divide properly.] *** Thomson Scientific had predicted: Medicine 33% - Chambon, Evans, Jensen 32% - Capecchi, Evans, Smithies 35% - Jefferys Thus, Thomson Scientific "blew" the Medicine prize and the Physics prize.

Tags: cell, rna, stem, medicine, silencing

Oral arguments in MedImmune v. Genentech were heard on October 4. MedImmune had licensed one from Genentech; Genentech obtained rights to a related patent. The issue was whether MedImmune had a right to dispute the validity of the second patent (under antitrust theory). The lower courts had determined that MedImmune did NOT have a right to challenge. Petitioner MedImmune argued against the CAFC's rule that a patent licensee cannot bring a declaratory judgment action questioning the validity of the licensed patent as long as the licensee has not breached the license agreement. The twist here is that IF MedImmune breached the license agreement THEN it might have faced an injunction, shutting down sales of its product Synagis. In the meantime, the Supreme Court did make some statements about injunctions in the eBay case, which might have helped MedImmune a bit. MedImmune also brings up Lear v. Adkins, 395 U.S. 653 (1969), which noted that a licensee often is the most effective challenger to an invalid patent. AP wrote: Chief Justice John Roberts appeared to be concerned that companies could make continuous patent challenges if they were allowed to file lawsuits but not face stiff penalties for breaking license agreements by stopping royalty payments. "How do you ever end these things? Let's say they have this dispute, they bring it to litigation, and they settle it," he said. "Instead of paying a license fee of 50 cents, it's going to be 40 cents, and we'll go on. Then they can sue again, I take it." Patent attorneys said if the case is decided in MedImmune's favor, it could lead to a flood of patent lawsuits because companies could challenge patents without risking legal penalties. But Washington attorney Harold C. Wegner, who watched Wednesday's arguments, said Roberts did not seem convinced by MedImmune's case. "The chief justice was very troubled by the idea," Wegner said. "What would stop the licensees from suing again and again?" generic cialis cheap viagra buy cheap cialis cialis

Tags: medimmune, patent, licensee, license, cialis

Electromagnetic Geoservices AS (emgs), a Norwegian support services provider for the oil and gas industry, has launched a legal action in Great Britain against Offshore Hydrocarbon Mapping PLC for patent infringement in the logging area. This brings up an interesting jurisdictional issue as to "where" to bring a patent law suit when one is logging (or performing other activities) in the open ocean.

Tags: logging, bring, mapping, emgs, patent

An article by Rita Vine in J Med Libr Assoc. 2006 January; 94(1): 97 viagra buy cilais cheap cialis

Tags: